Name of journal: World Journal of Clinical Cases
Manuscript NO: 70245
Title: Combination of atezolizumab and chidamide to maintain long-term remission in refractory metastatic extranodal natural killer/T-cell lymphoma: A case report
Provenance and peer review: Unsolicited manuscript; Externally peer reviewed
Peer-review model: Single blind
Reviewer’s code: 06111120
Position: Peer Reviewer
Academic degree: MD
Professional title: Doctor, Research Assistant
Reviewer’s Country/Territory: Iran
Author’s Country/Territory: China
Manuscript submission date: 2021-07-30
Reviewer chosen by: AI Technique
Reviewer accepted review: 2021-07-30 07:24
Reviewer performed review: 2021-08-07 10:16
Review time: 8 Days and 2 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>Grade B: Very good</th>
<th>Grade C: Good</th>
<th>Grade D: Fair</th>
<th>Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>Grade A: Priority publishing</td>
<td>Grade B: Minor language polishing</td>
<td>Grade C: A great deal of language polishing</td>
<td>Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>Accept (High priority)</td>
<td>Accept (General priority)</td>
<td>Minor revision</td>
<td>Major revision</td>
<td>Rejection</td>
</tr>
<tr>
<td>Re-review</td>
<td>Yes</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS

In this study, authors present a 56-year-old patient which was a previous case of extranodal natural killer (NK)/T-cell lymphoma (ENKTL) that was treated with combination of PD-L1 antibody, chidamide, and radiotherapy. This study is relevant. The organization & flow of the paper looks good. Title. The title reflects the main subject/hypothesis of the manuscript. 2 Abstract. The abstract summarizes and reflects the work described in the manuscript. 3 Key words. The key words reflect the focus of the manuscript. 4 Background. The manuscript adequately describes the background, present status and significance of the study. 5 Methods. The manuscript describes methods in adequate detail. 6 Results. Are the research objectives achieved by the experiments used in this study? What are the contributions that the study has made for research progress in this field? 7 Discussion. The manuscript interprets the findings adequately and appropriately, highlighting the key points concisely, clearly and logically. The discussion is accurate and discusses the paper’s scientific significance. 8 Illustrations and tables. The figures are sufficient. 9 Biostatistics. the manuscript meets the requirements of biostatistics. 10 Units. N/A 11 References. the manuscript cites appropriately the latest, important and authoritative references in the introduction and discussion sections. 12 Quality of manuscript organization and presentation. The manuscript is concisely written. Comments are provided to improve clarity and strengthen the manuscript: -There has been a trial evaluating the effects of a PD-L1 antibody plus Chidamide for r/r-ENKTL. A study by Yan Gao et al. conducted from March 2019 to May 2020, evaluated the efficacy of Sintilimab plus Chidamide on 37 ENKTL patients. This drug combination showed effective antitumor activity, and
durable response in patients with r/r-ENKTL. (https://doi.org/10.1182/blood-2020-134665). Please be very clear about what your study adds to the existing literature and clearly detail learning points? - There have been few case reports evaluating the combination effects of PD-L1 antibody plus Chidamide for r/r-ENKTL. Please provide a table on literature review and a comment should be made about this table. In other words, a paragraph should be written about some parameters such as the age, gender, type of treatment, and follow-up period of the patients - The data presented could stand from some fine tuning. Please proofread the manuscript carefully. - Please cite the CARE 2016 paper above in your text. https://doi.org/10.1016/j.ijsu.2016.08.014